Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis - Summary - MDSpire
Advertisement
Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an updated meta-analysis
To estimate the proportion of seroconversion following complete primary vaccination in SARS-CoV-2-naive patients with hematologic malignancies.
Key Findings:
Approximately two-thirds of hematologic malignancy patients achieved anti-spike SARS-CoV-2 IgG seroconversion after complete vaccination, compared to about 90% of patients with solid cancers.
Cell-mediated immune responses may provide protection in patients with impaired humoral immunity.
The impact of booster doses on seroconversion in hematologic malignancies remains largely undefined.
Interpretation:
Hematologic malignancy patients exhibit lower seroconversion rates post-vaccination compared to solid cancer patients, underscoring the need for tailored vaccination strategies and further research on cellular immune responses.
Limitations:
Limited studies evaluating T-cell responses.
Insufficient data on the impact of booster doses across diverse subgroups of hematologic malignancies.
Potential biases in the studies reviewed.
Conclusion:
The study underscores the importance of understanding immune responses in hematologic malignancy patients to improve vaccination strategies against SARS-CoV-2.
